News
SHANGHAI, China I May 15, 2025 I Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for ...
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback